AI Summary
This study highlights the significant improvement in long-term survival rates for patients with metastatic melanoma treated with immune checkpoint inhibitors. The landmark international trial showed that about half of the patients remained cancer-free for 10 years or more after treatment. This finding demonstrates the promising potential of immunotherapy in significantly improving outcomes for patients with advanced melanoma.
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report.